Why the Small-Mid CDMO Ecosystem Matters Now
For Korean biotech ventures and small-to-mid pharmaceutical companies, the first bottleneck after identifying a drug candidate is often the stable supply of core materials such as antigens and antibodies. Companies without in-house infrastructure to produce standardized antigens and antibodies are forced to rely on overseas material suppliers or a handful of large contract development and manufacturing organizations (CDMOs), which frequently leads to long lead times and rising costs that disrupt entire pipeline schedules. In practice, sourcing a single recombinant antigen needed for antibody candidate screening from overseas can take several months, and large CDMOs tend to deprioritize small, multi-item orders — a structural limitation that hits smaller players hardest. Against this backdrop, the government is shifting policy toward easing the concentration of supply chains around a small number of global CDMOs and helping domestic small-to-mid CDMOs build their own antigen-antibody production and process development capabilities.
Program Overview
This year, the government is running a bio-sector track under the National Advanced Strategic Industry Cluster Collaboration R&D Support Program, which funds joint consortia of materials/parts companies and finished-drug or CDMO companies within designated clusters to co-develop process localization and scale-up technologies. A flagship example is the antigen-antibody material bank project centered in Hongcheon, Gangwon Province, which aims to build a standardized antigen-antibody library that biotech companies both inside and outside the region can share. By having the material bank absorb material development and quality-control costs that individual companies would otherwise struggle to bear alone, the project is expected to significantly lower early-stage development costs for small and mid-sized firms and accelerate the pace of drug candidate validation. The initiative is also linked to the Ministry of Trade, Industry and Energy's "Open Bio-Industry Ecosystem Promotion Program," designed to combine the antigen-antibody resources secured through the material bank with process development services from small-to-mid CDMOs — ultimately raising the self-sufficiency of Korea's broader bio ecosystem.
Eligibility and Application Requirements
Eligible applicants are small and mid-sized biotech companies that are participating in, or planning to participate in, the material supply chain within a National Advanced Strategic Industry Cluster. Rather than applying alone, most successful applications form a consortium bringing together material suppliers, CDMOs, and demand-side companies (drug developers). Evaluators focus on: ▲ how clearly roles are divided within the consortium; ▲ whether a standardization and quality-control system for antigen-antibody materials is in place; ▲ actual or planned participation in production and supply chains within the cluster; and ▲ how concrete the localization-rate targets are. Consortia that present quantitative plans for utilizing the material bank and a clear process scale-up roadmap in their business plans tend to score higher, which makes it critical to define partner selection and role division clearly from the earliest planning stages.
KITIM's Consulting Support
KITIM advises companies preparing applications for the National Advanced Strategic Industry Cluster Collaboration R&D Support Program and the Open Bio-Industry Ecosystem Promotion Program, helping them draft R&D plans and business proposals. Given that these programs require consortium formation, KITIM supports partner matching among material suppliers, CDMOs, and demand-side companies, and works with each company to assess its existing facilities and workforce to build a realistic materials localization roadmap. For companies considering a shift toward small-to-mid CDMO operations or entry into the antigen-antibody materials business, now is an opportune time to use government support programs to reduce upfront investment burdens. If you have questions about participation strategy or application drafting, please contact the KITIM consulting team.